Abstract: Various shaped abrasive particles are disclosed. Each shaped abrasive particle includes a body having at least one major surface and a side surface extending from the major surface.

Abstract: A composite container having a paperboard hollow body with top and bottom open ends. The body is formed by a sidewall with inner and outer surfaces. The composite container includes a body liner extending peripherally about the inner surface of the body and a base connectable to the bottom open end of the hollow body. The base includes a sidewall sized and shaped to fit snugly within the bottom open end of the body. The sidewall is permanently coupled to a bottom portion of the liner. The composite container also includes a collar connectable to the top open end of the hollow body. The collar has a peripheral portion that abuts the top open end and an inner circumferential flange sized and shaped to fit snugly within the top open end of the body. The inner circumferential flange is permanently coupled to a top portion of the liner.

Abstract: A composite container having a paperboard hollow body with top and bottom open ends. The body is formed by a sidewall with inner and outer surfaces. The composite container includes a body liner extending peripherally about the inner surface of the body and a base connectable to the bottom open end of the hollow body. The base includes a sidewall sized and shaped to fit snugly within the bottom open end of the body. The sidewall is permanently coupled to a bottom portion of the liner. The composite container also includes a collar connectable to the top open end of the hollow body. The collar has a peripheral portion that abuts the top open end and an inner circumferential flange sized and shaped to fit snugly within the top open end of the body. The inner circumferential flange is permanently coupled to a top portion of the liner.

Abstract: A composite container having a paperboard hollow body with top and bottom open ends. The body is formed by a sidewall with inner and outer surfaces. The composite container includes a body liner extending peripherally about the inner surface of the body and a base connectable to the bottom open end of the hollow body. The base includes a sidewall sized and shaped to fit snugly within the bottom open end of the body. The sidewall is permanently coupled to a bottom portion of the liner. The composite container also includes a collar connectable to the top open end of the hollow body. The collar has a peripheral portion that abuts the top open end and an inner circumferential flange sized and shaped to fit snugly within the top open end of the body. The inner circumferential flange is permanently coupled to a top portion of the liner.

Abstract: A composite container having a paperboard hollow body with top and bottom open ends. The body is formed by a sidewall with inner and outer surfaces. The composite container includes a body liner extending peripherally about the inner surface of the body and a base connectable to the bottom open end of the hollow body. The base includes a sidewall sized and shaped to fit snugly within the bottom open end of the body. The sidewall is permanently coupled to a bottom portion of the liner. The composite container also includes a collar connectable to the top open end of the hollow body. The collar has a peripheral portion that abuts the top open end and an inner circumferential flange sized and shaped to fit snugly within the top open end of the body. The inner circumferential flange is permanently coupled to a top portion of the liner.

Abstract: A composite container having a paperboard hollow body with top and bottom open ends. The body is formed by a sidewall with inner and outer surfaces. The composite container includes a body liner extending peripherally about the inner surface of the body and a base connectable to the bottom open end of the hollow body. The base includes a sidewall sized and shaped to fit snugly within the bottom open end of the body. The sidewall is permanently coupled to a bottom portion of the liner. The composite container also includes a collar connectable to the top open end of the hollow body. The collar has a peripheral portion that abuts the top open end and an inner circumferential flange sized and shaped to fit snugly within the top open end of the body. The inner circumferential flange is permanently coupled to a top portion of the liner.

Abstract: The present invention provides a recyclable composite container. The recyclable composite container comprises a cardboard hollow body having an open end defining an opening. The body is formed by a sidewall having an inwardly rolled rim at the open end. The container also comprises a framing element which is removably connectable to the open end of the cardboard hollow body. The framing element has a peripheral portion and a hook-shaped connector linked to this peripheral portion. The connector is for engaging with the inwardly rolled rim of the cardboard hollow body. Such construction thereby allows connection of the framing element to the cardboard hollow body by hooking the connector to the rim of the cardboard hollow body, and disconnection of the framing element from the cardboard hollow body by pulling the framing element so as to disengage the connector from the rim.

Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.